Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Argifin is a synthetic oligopeptide and a potent chitinase inhibitor originally isolated from soil microorganisms. It acts as a sub-nanomolar inhibitor of several chitinases including those from Serratia marcescens (SmChiA and SmChiB), Aspergillus fumigatus (chitinase B1), and human chitotriosidase. Argifin has demonstrated IC50 values in the low micromolar to nanomolar range for these targets. Its primary mechanism is competitive inhibition of chitinases by binding to their active sites. Argifin is considered an experimental compound with no current clinical indications or approvals[1][3][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on argifin.